Evidence map›Paper›PMID 41422164›Full record

ArticleScientific reports2025

MiR-30a-5p activates the AKT signalling pathway by targeting PHTF2 to inhibit migration and EMT of gastric cancer.

Fei Tu, Fengyuan He, Zhiyuan Li, Yiqing Jia, Lingzhu Wang, Tiesuo Zhao, Sheng Guo, Yan Jin, Zhijun Yang

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Fei TuSchool of Forensic Medicine, Xinxiang Medical University, Xinxiang, China.
Fengyuan HeSchool of Forensic Medicine, Xinxiang Medical University, Xinxiang, China.
Zhiyuan LiSchool of Forensic Medicine, Xinxiang Medical University, Xinxiang, China.
Yiqing JiaXinxiang Engineering Technology Research Center of Immune Checkpoint Drug for Liver-Intestinal Tumors, Xinxiang Medical University, Xinxiang, China.
Lingzhu WangXinxiang Engineering Technology Research Center of Immune Checkpoint Drug for Liver-Intestinal Tumors, Xinxiang Medical University, Xinxiang, China.
Tiesuo ZhaoXinxiang Engineering Technology Research Center of Immune Checkpoint Drug for Liver-Intestinal Tumors, Xinxiang Medical University, Xinxiang, China.
Sheng GuoXinxiang Engineering Technology Research Center of Immune Checkpoint Drug for Liver-Intestinal Tumors, Xinxiang Medical University, Xinxiang, China.
Yan JinSchool of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, China.
Zhijun YangSchool of Forensic Medicine, Xinxiang Medical University, Xinxiang, China. zjyang@xxmu.edu.cn.

Funding

the Doctoral Scientific Research Foundation of Xinxiang Medical University 505117the Science and technology project of Henan Province No. 222102310513
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41422164
PMCPMC12835005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.